Home | Welcome to Contract Pharma   
Last Updated Thursday, July 31 2014
Print RSS Feed

WuXi PharmaTech Completes Suzhou Biosafety Testing Facility



Published May 13, 2014
Related Searches: Testing Development Preclinical
WuXi PharmaTech has completed construction of its new biosafety testing facility in Suzhou. The facility has 38,000 sq.-ft. of labs and support areas, and is located next to WuXi's GLP preclinical drug safety facility. Operations will begin this summer, once validations are completed. Service offerings will include clinical and commercial lot release programs, viral clearance testing, and virus and molecular-based safety detection services for local and multinational customers.
 
"WuXi's expanding capabilities help our customers advance their biologic product candidates through development more quickly and cost-effectively," said Dr. Ge Li, chairman and chief executive officer of WuXi PharmaTech. "By investing in capabilities that address our customers' needs, we have become a leading biologics solution provider."


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On